DigitalDx Ventures

Co-founder and General Partner of Colabora Ventures. He partnered with Alfredo Atanacio in 2009 to found UassistME, began angel investing in 2015, and co-founded real estate ventures and the Colabora Foundation before launching Colabora Ventures in 2021.

A private equity executive and venture capitalist who founded EXXclaim Capital, an early-stage fund focused on women's health, and co-founded the Evolvence India Life Science Fund. She previously was a partner at Skyline Ventures and TVM, and held roles at Genomics Collaborative and Roche.

Partner at DigitalDx Ventures with over 20 years in healthcare and financial services. Her investment career spans Loomis Sayles, Victoria 1522 Investments, Lido Advisors, Lyell Wealth Management, and Boston Private (acquired by SVB Private), and she previously worked as a lab scientist at the Whitehead Institute and biopharmaceutical companies including Praecis and Dyax. She holds a B.S. in Biology and an MBA from MIT.

Listed as the point of contact for inquiries at the firm.

Executive Director appointed in November 2012, responsible for supervising investment management and reviewing client portfolios and business performance. Previously Assistant Vice President at HSBC Broking Services (Asia) from 2005 to 2012 and an SFC licensed Responsible Officer.

David Kirk is a computer graphics and parallel computing pioneer with mechanical engineering degrees from MIT and a computer science PhD from Caltech. He held senior roles at NVIDIA including Chief Scientist and VP of Architecture, holds nearly 100 patents, was elected to the National Academy of Engineering, and authored a widely used parallel programming textbook while teaching as an adjunct professor at UIUC.

Physician and Clinical Associate Professor of Emergency Medicine at Stanford, and founder/CEO of concierge medicine practice The Village Doctor. He is a Venture Partner at DigitalDx Ventures and has held numerous medical leadership roles.

A cell and gene therapy, immunology, transplantation and healthcare expert with over 30 years of experience across healthcare, academia and biotechnology. She served as President and CEO of the California Institute for Regenerative Medicine (CIRM), earlier as a Stanford transplant surgeon and Associate Professor directing the Pediatric Organ Transplantation Program.

Medical technology investor with over 25 years of experience building healthcare companies. She was CEO and board member of Cala Health, led medtech investments for Johnson & Johnson Innovation (JJDC) for eight years, and previously worked as a healthcare investment banker at Goldman Sachs and Jefferies. She serves on the boards of RefleXion Medical and Neuropace, and holds degrees from Georgetown University and Columbia Business School.

A healthcare and MedTech executive with 25 years of global experience at companies including Google and Johnson & Johnson, where she served as Chief Strategy Officer for MedTech at Google Cloud and as a VP at J&J. She sits on the board of Pulmonx and is a Henry Crown Fellow of the Aspen Institute; this page appears in the DigitalDx EIR section.

Healthcare and digital health professional with 8+ years in business development and sales across healthcare organizations. Currently Head of Partnerships at Lapsi Health, advisor to Remedy Well, co-founder of OXYGEN Healthcare (acquired by Perthera.AI in 2022) and the MedTech Club community.

Anita Samarth is a health technology interoperability and digital health policy expert with over 25 years of experience across 200+ healthcare organizations. She is CEO and founder of Clinovations Government + Health and co-founded Clinovations LLC (acquired by the Advisory Board Company/Optum), and previously held roles at eHealth Initiative, GE Healthcare IT, First Consulting Group, and Accenture.

Listed as an Entrepreneur in Residence (EIR).

Digital health and life science investor currently VP of Strategic Partnerships at Caris Life Sciences, previously an Executive Director at Boehringer Ingelheim's Venture Fund over 14 years, and a lecturer at Stanford University School of Medicine. She holds a PhD in Pharmacogenomics and Bioinformatics from UCSF, a BS from Pomona College, and an MSc Eng from Stanford.

Listed as an Entrepreneur in Residence (EIR).

Drew Watson works in biostatistics, machine learning, and personalized medicine. He founded Nephrosant, a molecular diagnostics company focused on kidney health, and advises companies in personalized medicine, diagnostics, and pharmaceutical development. His earlier oncology work included contributing to the development of Oncotype DX for breast cancer and diagnostic tests for several other cancers. Before entering diagnostics, he advised international companies on quality management under Dr. W. Edwards Deming. He holds a BS in Statistics from California State University East Bay, an MS in Statistical Computing from Stanford University, a PhD in Biostatistics from UCLA, and an MBA from Golden Gate University.

Erin Niehaus joined DigitalDx Ventures after serving as a Vice President at J.P. Morgan Private Bank, where she advised VC and PE funds on financial planning, banking, liquidity, and investment management. She previously worked at Bordeaux Wealth Advisors and has over two decades of growth-investing experience in technology and healthcare, starting as an equity research analyst at Jennison Associates and later a portfolio manager at Bowman Capital.

Listed as an Entrepreneur in Residence (EIR).

Jasmine Kim is a marketing and general management executive with experience building and scaling businesses in digital media, commerce, and healthcare. She has held senior operating roles at Sutter Health, Johnson & Johnson (BabyCenter), Hayneedle/Walmart, ShopWell/IDEO, Expedia, Yahoo!, and P&G.

Listed as an Entrepreneur in Residence (EIR).

Listed as an Entrepreneur in Residence (EIR).

Michael Doherty is a pharmaceutical and diagnostics executive focused on precision medicine, with deep expertise in regulatory affairs and product development. He formerly served as Global Head of Pharma Regulatory Affairs at Roche/Genentech and helped secure approval of Foundation Medicine's F1CDx NGS panel; he now holds board and advisory roles at several life sciences companies.

Molly Martell has nearly 30 years of experience across prevention, treatment, and diagnostics products, most recently serving as Global Director for Diagnostics Value and Access at Amgen. She has expertise in sequencing technologies, blood-borne pathogens, and outbreak management, and has led companion diagnostics partnerships that expanded access to oncology and virology products in more than 40 countries. She holds a Bachelor of Arts from Pitzer College and a Master of Science from the London School of Economics and the London School of Hygiene and Tropical Medicine.

Richard Frank has three decades of international experience in regulatory labeling, coverage and payment, and clinical adoption of therapeutic and diagnostic drugs and devices, including AI. His work focuses on healthcare AI, including regulations, standards, coding, and coverage policy, as well as designing clinical trials programs and developing industry policy positions and public-private partnerships in healthcare delivery.

Listed as an Entrepreneur in Residence (EIR).

A physician, entrepreneur, and investor with 20+ years in healthcare, most recently Director at LabCorp's Corporate Venture Fund and Venture Partner at MedStartr and CancerFund. He co-founded MedVenture Catalyst and previously worked in venture development at UnitedHealth Group, corporate development at Freedom Meditech, and as a critical-care physician at Apollo Group in India.

Principal at DigitalDx Ventures who leads due diligence, works with portfolio companies, and drives fundraising. She previously spent over a decade at Mizuho Financial Group as VP of Business Development structuring financing solutions, and serves on the Education committee of 100 Women in Finance. She holds an MBA from San Jose State University.

Global business leader with over three decades of P&L, strategy and innovation experience at Johnson & Johnson, including serving as Worldwide President of Vision Care overseeing a $3.6B business, where he drove digital transformation and embedded a data-science culture. Holds a pharmaceutical sciences degree from Pune University and an MBA from IIM Calcutta.

Associate at DigitalDx Ventures who conducts due diligence, market research, and data analysis to evaluate investment opportunities, supports fundraising and LP outreach, and helps lead the fund's fellowship program. She also works as an Emerging Technology Researcher at Corewell Health and holds a BA in Entrepreneurship and Marketing from Grand Valley State University, with executive education from Columbia and UC Berkeley.

Biochemist and protein engineer specializing in the development and commercialization of point-of-care diagnostics, currently Head of Bio-logics at Cue Health. Over 20 years of biotech industry experience with prior roles at Pfizer, CalAsia Pharmaceuticals, and Alere Health, having developed antibodies, enzymes, and diagnostic reagents generating over $1B in revenue.

Vivian Lu is DigitalDx's Marketing Fellow, managing the firm's web presence and marketing materials, and serves as a venture capital intern. She studies Finance and Real Estate at The Wharton School and holds a certificate from Penn Carey Law School; she is also a nationally ranked Division 1 fencer and women's team captain.

Brings over 30 years in senior Technical Director roles with national housebuilders, providing development delivery, technical and planning leadership and overseeing regional operations.